Aurora Cannabis Inc. is open to considering a bid from a U.S. cannabis company looking to acquire the Edmonton-based company. The announcement of forming a special committee to review the unsolicited offer came shortly after Curaleaf Holdings Inc. disclosed its intentions to acquire all shares of Aurora.
If successful, the acquisition would result in the formation of a combined cannabis entity with a presence in 17 countries spanning Europe, North America, and other global markets, according to Curaleaf. The company, based in Stamford, Conn., and listed on the Toronto Stock Exchange, decided to publicly announce its bid after unsuccessful private negotiation attempts with Aurora’s leadership.
Curaleaf stated that despite sending a formal letter of intent on June 23 and a follow-up communication on July 7, Aurora’s board declined to engage in discussions. Curaleaf’s CEO expressed disappointment over the lack of engagement and emphasized the premium, strategic fit, and urgency of the proposal.
Proposing to pay Aurora shareholders $4 US per share plus an additional $0.75 US in cash per share, Curaleaf outlined its financial terms in its letters dated June 23 and July 7. However, Aurora disputed Curaleaf’s claim that it refused to engage, stating that ongoing communication between the companies’ representatives had occurred as recently as July 24.
Aurora plans to establish a special committee of independent directors to evaluate the proposal’s viability and alignment with stakeholders’ interests. The company cautioned that a deal is not guaranteed and operations will proceed as normal in the interim.
While acknowledging Curaleaf’s interest as positive, analysts raised concerns that the current offer “undervalues the long-term potential” of Aurora’s business. Noting Aurora’s market leadership, diverse product portfolio, strong financial position, and regulatory expertise, they believe the company has significant value creation prospects.
Curaleaf’s CEO highlighted the potential value creation through merging the companies, emphasizing the synergies between Curaleaf’s global distribution network and Aurora’s medical cannabis expertise and production capabilities. The combined revenue of over $1.5 billion US in the last year and expected annual cost savings of at least $40 million US further support the rationale for the proposed takeover.
The merger is positioned as mutually beneficial for both Curaleaf and Aurora shareholders, offering an opportunity for Aurora investors to participate in a broader global platform and capitalize on U.S. regulatory trends.